Limits...
MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.

Liu W, Wang N, Lu M, Du XJ, Xing BC - Mol Med Rep (2016)

Bottom Line: The immunohistochemistry data indicated significant increase of the MBD2 expression level in 81 cases (50.94%) compared with the PTL tissues (0/159, 0%, P<0.001).Multivariate analysis revealed that MBD2 was an independent prognostic factor for overall survival [HR, 2.089; P=0.001] and disease-free survival (HR, 1.601; P=0.022).In conclusion, MBD2 expression was elevated in HCC tissue, which suggesting MBD2 as a candidate prognostic marker of HCC.

View Article: PubMed Central - PubMed

Affiliation: Hepatopancreatobiliary Surgery Department Ⅰ, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, P.R. China.

ABSTRACT
Methyl-CpG binding domain 2 (MBD2) leads to the silencing of methylated genes in cancer cells and was implicated in the activation of prometastatic genes in hepatocellular carcinoma (HCC). The present study aimed to investigate the expression status of MBD2 in HCC and the correlation with surgical outcomes. The correlation between clinical prognostic factors and MBD2 were also evaluated. MBD2 expression was analyzed by western blotting in 20 paired HCC and paratumor liver (PTL) tissues. In addition, immunohistochemistry was performed on the 159 HCC samples following hepatic resection performed between January 2003 and October 2008. The correlation between clinicopathological factors and MBD2 expression was also evaluated by statistical analysis to determine the prognostic value of MBD2 expression in HCC. Postoperative prognostic factors were evaluated using univariate and multivariate analyses. Compared with PTL tissues, MBD2 expression was shown to be upregulated in 10 of the 20 HCC tissues (50%) by western blotting. The immunohistochemistry data indicated significant increase of the MBD2 expression level in 81 cases (50.94%) compared with the PTL tissues (0/159, 0%, P<0.001). The upregulated MBD2 expression in HCC tissues was correlated with BCLC stage B, tumor size >5 cm and microscopic vascular invasion. Multivariate analysis revealed that MBD2 was an independent prognostic factor for overall survival [HR, 2.089; P=0.001] and disease-free survival (HR, 1.601; P=0.022). In conclusion, MBD2 expression was elevated in HCC tissue, which suggesting MBD2 as a candidate prognostic marker of HCC.

No MeSH data available.


Related in: MedlinePlus

Survival curves showing the correlation between MBD2 and OS or DFS following resection. Kaplan-Meier curve showing (A) OS and (B) DFS of patients with HCC post-resection with/without MBD2 expression. The OS (P=0.002) and DFS (P=0.006) are significantly different in MBD2 negative and postive patients. Kaplan-Meier curve showing (C) OS and (D) DFS of patients divided into four groups dependent on the level of MBD2 expression. There is a significant difference in OS between the negative staining and moderately positive staining groups (P<0.001), the negative staining and highly positive staining groups (P=0.008) and the faintly positive staining and the moderately positive staining groups (P=0.034). There is significant difference in DFS between negative staining and moderately positive staining (P=0.002), negative staining and highly positive staining (P=0.025). MBD2, methyl-CpG binding domain 2; OS, overall survival; DFS, disease free survival; (−), negative staining; (+), faintly positive staining; (++), moderately positive staining; and (+++) highly positive staining.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940051&req=5

f3-mmr-14-02-1617: Survival curves showing the correlation between MBD2 and OS or DFS following resection. Kaplan-Meier curve showing (A) OS and (B) DFS of patients with HCC post-resection with/without MBD2 expression. The OS (P=0.002) and DFS (P=0.006) are significantly different in MBD2 negative and postive patients. Kaplan-Meier curve showing (C) OS and (D) DFS of patients divided into four groups dependent on the level of MBD2 expression. There is a significant difference in OS between the negative staining and moderately positive staining groups (P<0.001), the negative staining and highly positive staining groups (P=0.008) and the faintly positive staining and the moderately positive staining groups (P=0.034). There is significant difference in DFS between negative staining and moderately positive staining (P=0.002), negative staining and highly positive staining (P=0.025). MBD2, methyl-CpG binding domain 2; OS, overall survival; DFS, disease free survival; (−), negative staining; (+), faintly positive staining; (++), moderately positive staining; and (+++) highly positive staining.

Mentions: Based on MDB2 immunohistochemical staining, 78 patients were negative for staining of MBD2 and 81 patients showed positive staining. The OS and DFS of MBD2-positive patients were less than those negative for MBD2 (P=0.002 for OS, P=0.006 for DFS, Fig. 3A and B). Moreover, based on the immunohistochemical staining, the OS and DFS for different levels of MBD2 expression significant different (P<0.01; Fig. 3C and D).


MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.

Liu W, Wang N, Lu M, Du XJ, Xing BC - Mol Med Rep (2016)

Survival curves showing the correlation between MBD2 and OS or DFS following resection. Kaplan-Meier curve showing (A) OS and (B) DFS of patients with HCC post-resection with/without MBD2 expression. The OS (P=0.002) and DFS (P=0.006) are significantly different in MBD2 negative and postive patients. Kaplan-Meier curve showing (C) OS and (D) DFS of patients divided into four groups dependent on the level of MBD2 expression. There is a significant difference in OS between the negative staining and moderately positive staining groups (P<0.001), the negative staining and highly positive staining groups (P=0.008) and the faintly positive staining and the moderately positive staining groups (P=0.034). There is significant difference in DFS between negative staining and moderately positive staining (P=0.002), negative staining and highly positive staining (P=0.025). MBD2, methyl-CpG binding domain 2; OS, overall survival; DFS, disease free survival; (−), negative staining; (+), faintly positive staining; (++), moderately positive staining; and (+++) highly positive staining.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940051&req=5

f3-mmr-14-02-1617: Survival curves showing the correlation between MBD2 and OS or DFS following resection. Kaplan-Meier curve showing (A) OS and (B) DFS of patients with HCC post-resection with/without MBD2 expression. The OS (P=0.002) and DFS (P=0.006) are significantly different in MBD2 negative and postive patients. Kaplan-Meier curve showing (C) OS and (D) DFS of patients divided into four groups dependent on the level of MBD2 expression. There is a significant difference in OS between the negative staining and moderately positive staining groups (P<0.001), the negative staining and highly positive staining groups (P=0.008) and the faintly positive staining and the moderately positive staining groups (P=0.034). There is significant difference in DFS between negative staining and moderately positive staining (P=0.002), negative staining and highly positive staining (P=0.025). MBD2, methyl-CpG binding domain 2; OS, overall survival; DFS, disease free survival; (−), negative staining; (+), faintly positive staining; (++), moderately positive staining; and (+++) highly positive staining.
Mentions: Based on MDB2 immunohistochemical staining, 78 patients were negative for staining of MBD2 and 81 patients showed positive staining. The OS and DFS of MBD2-positive patients were less than those negative for MBD2 (P=0.002 for OS, P=0.006 for DFS, Fig. 3A and B). Moreover, based on the immunohistochemical staining, the OS and DFS for different levels of MBD2 expression significant different (P<0.01; Fig. 3C and D).

Bottom Line: The immunohistochemistry data indicated significant increase of the MBD2 expression level in 81 cases (50.94%) compared with the PTL tissues (0/159, 0%, P<0.001).Multivariate analysis revealed that MBD2 was an independent prognostic factor for overall survival [HR, 2.089; P=0.001] and disease-free survival (HR, 1.601; P=0.022).In conclusion, MBD2 expression was elevated in HCC tissue, which suggesting MBD2 as a candidate prognostic marker of HCC.

View Article: PubMed Central - PubMed

Affiliation: Hepatopancreatobiliary Surgery Department Ⅰ, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, P.R. China.

ABSTRACT
Methyl-CpG binding domain 2 (MBD2) leads to the silencing of methylated genes in cancer cells and was implicated in the activation of prometastatic genes in hepatocellular carcinoma (HCC). The present study aimed to investigate the expression status of MBD2 in HCC and the correlation with surgical outcomes. The correlation between clinical prognostic factors and MBD2 were also evaluated. MBD2 expression was analyzed by western blotting in 20 paired HCC and paratumor liver (PTL) tissues. In addition, immunohistochemistry was performed on the 159 HCC samples following hepatic resection performed between January 2003 and October 2008. The correlation between clinicopathological factors and MBD2 expression was also evaluated by statistical analysis to determine the prognostic value of MBD2 expression in HCC. Postoperative prognostic factors were evaluated using univariate and multivariate analyses. Compared with PTL tissues, MBD2 expression was shown to be upregulated in 10 of the 20 HCC tissues (50%) by western blotting. The immunohistochemistry data indicated significant increase of the MBD2 expression level in 81 cases (50.94%) compared with the PTL tissues (0/159, 0%, P<0.001). The upregulated MBD2 expression in HCC tissues was correlated with BCLC stage B, tumor size >5 cm and microscopic vascular invasion. Multivariate analysis revealed that MBD2 was an independent prognostic factor for overall survival [HR, 2.089; P=0.001] and disease-free survival (HR, 1.601; P=0.022). In conclusion, MBD2 expression was elevated in HCC tissue, which suggesting MBD2 as a candidate prognostic marker of HCC.

No MeSH data available.


Related in: MedlinePlus